Replies to post #159768 on Biotech Values

[DewDiligence]

AMRN/OMTH—Are you suggesting Epanova is a serious competitor to Vascepa?

No, not at all. Rather, I was suggesting that the OMTH IPO may have gotten off to a bad start because investors are aware that AMRN has been a poor investment during the past year or so.